Alberto Papi
Impact in
- Physiology top 0.05%
- Asthma and respiratory diseases
- Pulmonary and Respiratory Medicine top 0.02%
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory and Cough-Related Research
- Respiratory Support and Mechanisms
- Inhalation and Respiratory Drug Delivery
Papers in
-
- Chronic Obstructive Pulmonary Disease (COPD) Research 170
- Respiratory and Cough-Related Research 61
- Inhalation and Respiratory Drug Delivery 54
- Respiratory Support and Mechanisms 38
- Physiology 234
- Asthma and respiratory diseases 231
- Co-authors
- Leonardo M. Fabbri (106 shared papers)Sebastian L. Johnston (51 shared papers)Gaetano Caramori (75 shared papers)Marco Contoli (90 shared papers)Helen K. Reddel (15 shared papers)Christopher E. Brightling (21 shared papers)Søren Pedersen (1 shared paper)Paolo Casolari (40 shared papers)
- Journals
- American Journal of Respiratory and Critical Care Medicine (31 papers)European Respiratory Journal (28 papers)Respiratory Medicine (16 papers)Journal of Allergy and Clinical Immunology (14 papers)CHEST Journal (14 papers)
- Partner nations
- ItalyUnited KingdomUnited States
In The Last Decade
Alberto Papi
465 papers receiving 22.9k citations
Alberto Papi's Hit Papers
Peers
Comparison fields: 5 of 169
- Physiology 9.7k
- Pulmonary and Respiratory Medicine 11.2k
- Emergency Medical Services 1.8k
- Immunology 3.3k
- Immunology and Allergy 885
Countries citing papers authored by Alberto Papi
This map shows the geographic impact of Alberto Papi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alberto Papi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alberto Papi more than expected).
Fields of papers citing papers by Alberto Papi
This network shows the impact of papers produced by Alberto Papi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alberto Papi. The network helps show where Alberto Papi may publish in the future.
Co-authors
The 25 scholars most cited alongside Alberto Papi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 497 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Asthma Hit paper breakdown → | 2017 | 1245 |
| 2 | Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial Hit paper breakdown → | 2016 | 1008 |
| 3 | Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations Hit paper breakdown → | 2006 | 786 |
| 4 | Role of deficient type III interferon-λ production in asthma exacerbations Hit paper breakdown → | 2006 | 780 |
| 5 | Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease Hit paper breakdown → | 2020 | 491 |
| 6 | Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline Hit paper breakdown → | 2017 | 459 |
| 7 | Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults Hit paper breakdown → | 2023 | 439 |
| 8 | 2000 | 411 | |
| 9 | Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial Hit paper breakdown → | 2018 | 411 |
| 10 | 2003 | 376 | |
| 11 | 2008 | 373 | |
| 12 | 2001 | 359 | |
| 13 | 2010 | 293 | |
| 14 | Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial Hit paper breakdown → | 2017 | 293 |
| 15 | Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial Hit paper breakdown → | 2016 | 288 |
| 16 | 2002 | 284 | |
| 17 | 2019 | 276 | |
| 18 | Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision Hit paper breakdown → | 2022 | 269 |
| 19 | 1999 | 268 | |
| 20 | 2009 | 254 |
About Alberto Papi
Alberto Papi is a scholar working on Pulmonary and Respiratory Medicine, Physiology, Immunology, Epidemiology and Emergency Medical Services, having authored 497 papers that have together received 23.3k indexed citations. Recurring topics across this work include Asthma and respiratory diseases (231 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (170 papers), Respiratory and Cough-Related Research (61 papers), Inhalation and Respiratory Drug Delivery (54 papers), Respiratory Support and Mechanisms (38 papers), Pediatric health and respiratory diseases (30 papers), IL-33, ST2, and ILC Pathways (29 papers) and Respiratory viral infections research (28 papers). The work is most often cited by research in Physiology (9.7k citations), Pulmonary and Respiratory Medicine (11.2k citations), Emergency Medical Services (1.8k citations), Immunology (3.3k citations) and Immunology and Allergy (885 citations). Alberto Papi has collaborated with scholars based in Italy, United Kingdom and United States. Frequent co-authors include Leonardo M. Fabbri, Sebastian L. Johnston, Gaetano Caramori, Marco Contoli, Helen K. Reddel, Christopher E. Brightling, Søren Pedersen, Paolo Casolari, Dave Singh and Marina Saetta. Their work appears in journals such as American Journal of Respiratory and Critical Care Medicine, European Respiratory Journal, Respiratory Medicine, Journal of Allergy and Clinical Immunology and CHEST Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.